Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Toscano

Showing results (121-130 of 223) with videos related to

Pageof 23
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 26, 2020
Which are the factors influencing NIV adaptation and tolerance in ALS patients?Massimo Russo, Carmen Bonanno, Claudia Profazio, et al.
European Journal of Neurology|December 12, 2023
A strategic neurological research agenda for Europe: Towards clinically relevant and patient-centred neurological research prioritiesPaul Boon, Emma Lescrauwaet, Katina Aleksovska, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 5, 2021
Ischemic Stroke and Asymptomatic Pulmonary OpacitiesCarmelo Tiberio Currò, Masina Cotroneo, Antonio Ciacciarelli, et al.
Neurology|February 20, 2025
Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003)Hani Kushlaf, Drago Bratkovic, Barry Byrne, et al.
Brain Sciences|January 20, 2021
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular DystrophyGian Luca Vita, Maria Sframeli, Norma Licata, et al.
Human Mutation|August 16, 2005
Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophiesRachele Cagliani, Francesca Magri, Antonio Toscano, et al.
Human Mutation|June 21, 2006
McArdle disease: the mutation spectrum of PYGM in a large Italian cohortClaudio Bruno, Denise Cassandrini, Andrea Martinuzzi, et al.
Molecular Genetics and Metabolism|January 6, 2024
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trialAntonio Toscano, Laurence Pollissard, Jérôme Msihid, et al.
Minerva Anestesiologica|July 5, 2023
The safety of thoracic paravertebral block and erector spinae plane block in patients treated with anticoagulant or antiplatelet therapy. A narrative review of the evidenceFulvio Nisi, Nicolò Sella, Guido DI Gregorio, et al.
Journal of Neurology|February 5, 2021
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfaKristina Gutschmidt, Olimpia Musumeci, Jordi Díaz-Manera, et al.
Pageof 23

Showing results (121-130 of 223) with videos related to

Sort By:
Pageof 23
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 26, 2020
Which are the factors influencing NIV adaptation and tolerance in ALS patients?Massimo Russo, Carmen Bonanno, Claudia Profazio, et al.
European Journal of Neurology|December 12, 2023
A strategic neurological research agenda for Europe: Towards clinically relevant and patient-centred neurological research prioritiesPaul Boon, Emma Lescrauwaet, Katina Aleksovska, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|December 5, 2021
Ischemic Stroke and Asymptomatic Pulmonary OpacitiesCarmelo Tiberio Currò, Masina Cotroneo, Antonio Ciacciarelli, et al.
Neurology|February 20, 2025
Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003)Hani Kushlaf, Drago Bratkovic, Barry Byrne, et al.
Brain Sciences|January 20, 2021
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular DystrophyGian Luca Vita, Maria Sframeli, Norma Licata, et al.
Human Mutation|August 16, 2005
Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophiesRachele Cagliani, Francesca Magri, Antonio Toscano, et al.
Human Mutation|June 21, 2006
McArdle disease: the mutation spectrum of PYGM in a large Italian cohortClaudio Bruno, Denise Cassandrini, Andrea Martinuzzi, et al.
Molecular Genetics and Metabolism|January 6, 2024
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trialAntonio Toscano, Laurence Pollissard, Jérôme Msihid, et al.
Minerva Anestesiologica|July 5, 2023
The safety of thoracic paravertebral block and erector spinae plane block in patients treated with anticoagulant or antiplatelet therapy. A narrative review of the evidenceFulvio Nisi, Nicolò Sella, Guido DI Gregorio, et al.
Journal of Neurology|February 5, 2021
STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfaKristina Gutschmidt, Olimpia Musumeci, Jordi Díaz-Manera, et al.
Pageof 23